The PennZone

  • Home
  • Business
  • Health
  • Non-profit
  • Education
  • Technology
  • Entertainment
  • Financial
  • Marketing

iECURE Enters Agreement with Center for Breakthrough Medicines (CBM) to Supply Materials for Future Clinical Programs
The PennZone/10184039

Trending...
  • xREnergy up as much as +3,094,634% on first day listed on the XRP Ledger. Ticker : $XRE
  • Bonelli Systems Expands Managed IT Services Nationwide, Leveraging Microsoft Azure Expertise
  • The Tide Project Opens at Biennale Architettura 2025 in Venice Amplifying Youth Voices
PHILADELPHIA--(BUSINESS WIRE)--iECURE, a gene editing company focused on mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need, and Center for Breakthrough Medicines (CBM) today announced the companies have entered into a strategic collaboration wherein CBM will produce and supply Good Manufacturing Practices (GMP)-grade adeno-associated virus (AAV) for use in iECURE's future clinical studies to enable development of iECURE's programs with the shared mission of accelerating the availability of these potential treatments to the patients.

"Our approach to gene editing relies on highly complex manufacturing processes, and we are eager to establish partnerships to ensure a reliable supply of GMP materials for future clinical development," said Paul Firuta, Chief Operating Officer of iECURE. "CBM was able to offer us significant amount of guaranteed capacity with scheduling flexibility and we are confident that they will be a strong partner with their state-of-the-art facilities and end-to end capabilities."

More on The PennZone
  • Exciting First Five Months Of 2025 At Aiatranslations
  • Fairmint Introduces First Fully Onchain and Open Cap Table Infrastructure
  • Vortex Brands Begins Gold Purchases Under New Joint Venture with Dubai-Based Partner
  • Author Chandra Donelson Visits the Children's Museum of Pittsburgh
  • Chandra Donelson Headlines the Hike2 Innovation Summit 2025

"iECURE's approach to gene editing is quite innovative and has the potential to bring significant hope to patients and families facing devastating diagnoses," said Audrey Greenberg, Chief Business Officer and Co-Founder of CBM. "Our ability to provide customizable clinical and commercial GMP manufacturing solutions integrated with industry-leading comprehensive in-process testing, quality control, and lot release programs allows us to support our partners like iECURE through the entirety of their product lifecycle and is aligned with our mission to bring life changing medicines to patients in need."

About iECURE

iECURE is a gene editing company focused on developing therapies that utilize mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of monogenic liver disorders with significant unmet need. We believe our approach has the potential to replace and restore the function of a dysfunctional gene by knocking-in a healthy copy, regardless of mutation, to offer durable gene expression and long-term, potentially curative, therapeutic benefit. Our management team has extensive experience in executing global orphan drug and gene therapy clinical trials and successfully commercializing multiple products. We intend to leverage our team's core strength in research and development strategy to identify what we believe to be the most suitable target and modality for our product candidates to address particular liver diseases. We are collaborating with the University of Pennsylvania's Gene Therapy Program, or GTP, led by James M. Wilson, M.D., Ph.D., to utilize GTP's world-class translational expertise and infrastructure, which has helped generate our initial pipeline of potential product candidates. For more information, visit www.iecure.com and follow on LinkedIn.

More on The PennZone
  • NBA Champion Lamar Odom Launches Anti-Addiction Meme Coin, Ushering in a Disruptive Innovation in Web3
  • Aureli Construction Sets the Standard for Seamless Home Additions in Greater Boston
  • Actuated Medical Launches Participating Preferred Series A Round, Led by Keiretsu Forum Mid-Atlantic, South-East, & Texas
  • ScreenPoints Puts Film Investors in the Credits—and in the Money With New FinTech Platform
  • Viatris Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Novel Fast-Acting Meloxicam (MR-107A-02) for the Treatment of Moderate-to-Severe Acute Pain

About Center for Breakthrough Medicines (CBM)

CBM is a cell and gene therapy contract development and manufacturing organization (CDMO) based in the heart of Philadelphia's Cellicon Valley. CBM offers pre-clinical through commercial manufacturing capabilities including process development, plasmid DNA, viral vector, cell therapy and a full suite of testing and analytical capabilities. Through a single-source, end-to-end solution, CBM accelerates time to market without compromising quality.

Contacts

Investors:
David Garrett
dgarrett@iecure.com

Media:
Danielle Cantey
Canale Communications
danielle.cantey@canalecomm.com
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Nurse leader Julie Nyhus has been named editorial director of American Nurse Journal
  • ABM for Good™ Launches First Project with Build Change
  • Braces for Teenagers in Allentown Offered by Exeter Smiles
  • Roots for Boots to Host "Bike Day Bash" Featuring Trike Presentation to Local Veteran
  • JOSHWAY Cuts Ribbon on New Brick-and-Mortar Location
  • ImagineX, in Collaboration with Qualys, Launches New mROC Services to Transform Enterprise Cyber Risk Management
  • Ditch Micromanagement: New Leadership Book for Results-Driven, Accountability-Based Teams
  • Jay Tapp was named Managing Director in British Columbia
  • Children's Hospital of Philadelphia Researchers Recommend New Standard of Care for Families with Hereditary Neuroblastoma Linked to ALK Mutation
  • GormanSquared Announces Provisional Patent
  • Hubei Heavy Equipment Makes a Striking Appearance at CIMT and Competes with International Brands
  • 20 Patents Issued Worldwide, Cementing Company Leadership. First Ever Cable-Free 12-Lead ECG: HeartBeam, Inc. (Stock Symbol: BEAT)
  • NASDAQ Uplisting for Higher Market Exposure and Wide Corporate Benefits to AI Boosted Marketing Company On Track Towards $1 Billion Revenue by 2027
  • Congressional Men's Health Caucus Shows Bipartisan Consensus and Focus on Prevention, Mental Health, and Closing the Lifespan Gap
  • Chewy Chums™ Launches NeverBite™ on Kickstarter
  • DuoKey, Axiomtek and Blue Edge Network Partner to Enhance Smart Cities with Privacy-Preserving Urban Safeguarding and Fleet Management
  • Fangzhou Launches Otsuka's Third-Generation Leukemia Drug Ponatinib on its Platform
  • Viatris Announces Appointments of Frank D'Amelio and Michael Severino, M.D., to the Company's Board of Directors
  • Austin Keen Joins WakeFX RopePal as Official Brand Ambassador
  • Bonelli Systems Expands Managed IT Services Nationwide, Leveraging Microsoft Azure Expertise

Popular on PennZone

  • Gas Wolf® Officially Becomes a Registered Trademark - 1292
  • Village Vapes and Cooking 4 Autism Announce Inaugural Partnership at MEGA 420 EVENT - 141
  • Jed the Fish, The Rapscallion of Los Angeles KROQ's Airwaves and Provocateur, Has Signed Off at 69 - 120
  • The World's No.1 Superstar Champions the NO FAKES Act – Secures Global Identity and Cultural Legacy
  • Goosechase Rolls Out Unlockable Missions, Its Most Anticipated Feature Yet
  • Portland Hosts Mensa's 2025 Mind Games®
  • PebblePad Welcomes Justin Reilly as New CEO to Drive Innovation and Growth
  • HR Tech Awards Program Celebrates 6th Year: Showcases Top Hiring, Talent, and HR Technologies
  • Museum Hack Presents Hacked Gala: A Rebellious Night of Art, Fashion, and Change at the Met
  • Damian Redd's "Caught in a Fantasy" Surpasses 100,000 Views on VEVO/YouTube Following Album Reissue

Similar on PennZone

  • PBK Miner completes $80 million Series B financing to support AI cloud mining and increase user investment return by 25%
  • Asset-Backed Green Crypto: Fueling the Trillion-Dollar Revolution
  • QVC Honors Elton John with Inaugural Icon Award
  • NBA Champion Lamar Odom Launches Anti-Addiction Meme Coin, Ushering in a Disruptive Innovation in Web3
  • Viatris Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Novel Fast-Acting Meloxicam (MR-107A-02) for the Treatment of Moderate-to-Severe Acute Pain
  • Cybersecurity is Protecting Your Personal Information and Your Portfolio
  • The Paris Court of International Arbitration Elects Dr. John J. Maalouf as its New President
  • $56.7 Million Announced in Q1 2025 with Revenue Growth and Progress Toward NASDAQ Uplisting for AI Marketing Company: IQSTEL, Inc. Stock Symbol: IQSTD
  • SAVVY MINING raised $500 million and launched BTC.XRP.DOGE cloud mining, increasing investors' returns by 30%
  • Ditch Micromanagement: New Leadership Book for Results-Driven, Accountability-Based Teams
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us